	US 12,472,224 B2
	Ready-to-use bivalirudin compositions
Srikanth Sundaram, Somerset, NJ (US)
Assigned to MAIA PHARMACEUTICALS, INC., Princeton, NJ (US)
Filed by MAIA Pharmaceuticals, Inc., Princeton, NJ (US)
Filed on Jan. 30, 2024, as Appl. No. 18/426,692.
Application 18/426,692 is a continuation of application No. 18/060,529, filed on Nov. 30, 2022, granted, now 11,918,622.
Application 18/060,529 is a continuation of application No. 16/417,362, filed on May 20, 2019, granted, now 11,992,514.
Prior Publication US 2024/0165194 A1, May 23, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/10 (2006.01); A61K 9/00 (2006.01); A61K 38/58 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61P 7/02 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01)

CPC A61K 38/10 (2013.01) [A61K 9/0019 (2013.01); A61K 38/58 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61P 7/02 (2018.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01)]

20 Claims

1. A ready-to-use liquid composition comprising about 5 mg/mL bivalirudin or a salt thereof, about 0.8 mg/mL sodium acetate, about 100 mg/mL PEG 400, and water and optionally, glacial acetic acid and/or sodium hydroxide, wherein the composition has a pH of from greater than 5.0 to 5.7.